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MaOBJECTIVES The aim of this study was to examine the chronic effects of polyvinyl-alcohol (PVA) injection on mitral regur-
gitation (MR) reduction, mitral valve geometry, and left ventricular (LV) remodeling in a chronic ischemic MR sheep model.
BACKGROUND Previous studies have demonstrated acute efﬁcacy of PVA hydrogel polymer injection into infarcted
myocardium underlying the papillary muscle to relieve MR by papillary muscle repositioning. However, the chronic
efﬁcacy of PVA injection in the chronic infarction setting remains unclear.
METHODS Sixteen sheep developed chronic MR 8 weeks after induced inferoposterior myocardial infarction. Ten
consecutive sheep underwent PVA injection (PVA group) and 6 sheep served as control subjects with saline injection.
Epicardial 2-/3-dimensional echocardiography was performed at the baseline, chronic MR (pre-injection), and sacriﬁce
(8 weeks after injection) stages.
RESULTS Both groups were comparable at the baseline and chronic MR stages. At sacriﬁce, MR decreased from moderate
to trace or mild (vena contracta: 0.17  0.08 cm vs. 0.56  0.10 cm, p < 0.001) in the PVA group but progressed to
moderate to severe in the control group. End-systolic and -diastolic volumes remained stable in the PVA group but increased
signiﬁcantly in the control group (both p < 0.05). At sacriﬁce, compared with the control group, the PVA group had
signiﬁcantly less left ventricular remodeling (end-systolic volume: 41.1  10.4 ml vs. 55.9  12.4 ml, p < 0.05), lower MR
severity (vena contracta: 0.17  0.08 cm vs. 0.60  0.14 cm, p < 0.01), and favorable changes in mitral valve geometry.
CONCLUSIONS Polymer injection in a chronic ischemic MR model results in persistent reduction of MR and attenuation
of continued left ventricular remodeling over 8 weeks of follow-up. (J Am Coll Cardiol Intv 2015;8:355–63) © 2015 by
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EDV = end-diastolic volume
EF = ejection fraction
ESV = end-systolic volume
IMR = ischemic mitral
regurgitation
IPMD = interpapillary muscle
distance
LA = left atrial
LV = left ventricular
MI = myocardial infarction
MR = mitral regurgitation
PM = papillary muscle
PVA = polyvinyl alcohol
VC = vena contracta
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356I schemic mitral regurgitation (IMR) is acommon complication of myocardialinfarction (MI). Mild or greater IMR
occurs in 42% to 50% of patients within 30
days following acute MI, among which about
12% of patients had moderate or greater MR
(1,2). Importantly, the presence of even mild
MR is associated with increased mortality
risk and reduced survival (3). Additionally,
up to 50% of patients with LV systolic
dysfunction from either ischemic or noni-
schemic etiologies have moderate or greater
MR, representing high-risk subsets (4).
Currently, surgical management of moderate
or severe IMR is recommended by the Amer-
ican College of Cardiology/American Heart
Association guidelines (5). Ring annuloplasty
is the most commonly used procedure, which
downsizes the mitral annulus to improve
coaptation and reduce the MR. However,larger series show there is an approximately 30%
recurrence rate of IMR 1 year after mitral repair and
the prevalence increases with time (6). Treatment op-
tions for IMR have recently been expanded with the
development of percutaneous mitral valve repair.SEE PAGE 364The mechanisms of IMR relate to leaﬂet tethering
due to papillary muscle (PM) displacement secondary
to ischemic left ventricular (LV) wall distortion, with
a contribution from annular dilation. Either surgical
or percutaneous mitral valve repair does not address
the ventricular problem, so that leaﬂet tethering and
continued LV remodeling appear to account for the
high incidence of recurrent MR (7,8). On the other
hand, surgical strategies that directly target the LV
distortion have demonstrated efﬁcacy in reducing
recurrent MR by attenuating leaﬂet tethering, such
as infarct plication or external constraint using a
patch with an adjustable balloon device over the
infarcted LV (9). However, these techniques remain
relatively invasive.
Injection of polymers into an infarcted myocar-
dium is a novel approach to treat IMR, with the po-
tential to not only reduce IMR but also to stabilize
adverse LV remodeling by acting as a tissue-bulking
agent. Polyvinyl alcohol (PVA) polymer is a biocom-
patible and biologically inert material that can be
formulated to be injectable and form a stable solid gel
once it has been injected into the myocardium. Our
previous studies have demonstrated acute efﬁcacy of
PVA hydrogel polymer injection into an infarcted
myocardium underlying the PM to relieve IMR in both
acute and chronic IMR models (10,11). The mechanismof MR reduction immediately after PVA injection
is associated with repositioning of the papillary
muscle. In the present study, we aim to examine the
long-term efﬁcacy of PVA injection in MR reduction
and LV remodeling in the setting of chronic MI. IMR is
most often encountered in the chronic infarction
setting and both MR recurrence and LV remodeling
are of particular relevance to adverse outcomes. We
hypothesized that chronic localized PVA hydrogel
injection can stabilize the mitral valve–LV spatial
relationship, resulting in the beneﬁcial effects on
persistent MR reduction and attenuation of LV
remodeling in the setting of chronic MI.METHODS
STUDY DESIGN. The study design is illustrated in
Figure 1. As detailed by Llaneras et al. (12), infer-
oposterior MI was created in Polypay sheep by liga-
tion of the second and third circumﬂex marginal
branches. A chronic IMR model was produced 8
weeks after ligation, and animals underwent a sec-
ond thoracotomy for injection of PVA polymer (PVA
group) or saline (control group). Animals were
observed for a further 8 weeks after injection. A third
thoracotomy was performed to evaluate the chronic
efﬁcacy of the treatment and then the animals were
euthanized.
Epicardial 2-dimensional (2D) and 3-dimensional
(3D) echocardiography were performed at baseline,
at the chronic MR stage (before injection), and at
sacriﬁce (8 weeks after injection). Hemodynamic
assessment was performed at the chronic MR stage
and at sacriﬁce. This study was approved by our
institutional Animal Care Committee.
PVA HYDROGEL POLYMER INJECTION. Preparation
and injection of PVA hydrogel was performed as
previously described (10,11). An 11% PVA hydrogel
aqueous solution (Cambridge Polymer Group, Inc.,
Boston, Massachusetts) was pre-formulated, steril-
ized, and stored in 10-ml syringes at room tempera-
ture (20C to 30C) as a solid gel. This PVA
formulation was designed to gel at or near body
temperature (below 45C). The PVA hydrogel syringes
were heated to over 90C in a water bath to achieve
liquid state and then allowed to cool to 39C to 40C
before injection. Location of injection was identiﬁed
to be within the scar tissue of the inferoposterior wall,
as guided by direct visualization of the infarcted
myocardium. Once identiﬁed, this area was manually
compressed inward with a displacement of about 1 cm
with real-time echocardiographic imaging to conﬁrm
reduction in MR. The PVA hydrogel was then injected
FIGURE 1 Study Design
Posterolateral myocardial infarction (MI) was induced by ligation of circumﬂex marginal
branches in sheep. Chronic ischemic mitral regurgitation (MR) was developed 8 weeks after
infarction. Animals were then divided into polyvinyl-alcohol (PVA) injection and control
groups. Eight weeks after injection, the animals were sacriﬁced. Echocardiography was
performed at baseline, prior to injection, and 8 weeks after injection.
FIGURE 2 Schematic of PVA Injection
Schematic of PVA injection into infarcted myocardium underlying papillary muscle (PM) to
attenuate leaﬂets tethering and reduce MR. AO ¼ aorta; other abbreviation as in Figure 1.
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357into the target area underlying the PM using an
18-gauge short-bevel needle at a 45 angle relative to
the myocardium (Figure 2). The amount of polymer
injected can be guided by echocardiographic assess-
ment of MR if satisfying reduction is achieved. Each
injection contained 1 to 2 ml of PVA hydrogel. If MR
remained greater than mild after a total of 2 ml of PVA
injected, a repeat injection was performed in an
adjacent region within 1 to 2 cm of the initial injection
site. Maximal PVA volume injected did not exceed a
total of 5 ml.
The control group was treated with an injection of
saline into the target area with a similar volume as
that of injected PVA.
ECHOCARDIOGRAPHY. Epicardial 2D and 3D echo-
cardiography were performed using iE33 ultrasound
system equipped with S5-1 and X3-1 transducers (Phi-
lips Medical Systems, Andover, Massachusetts). The
2D measurements included vena contracta (VC) width
for MR quantiﬁcation (10), LV end-systolic volume
(ESV) and end-diastolic volume (EDV) by the biplane
Simpson method, and left atrial (LA) volume by
biplane area-length method. LV ejection fraction (EF)
was calculated. The 3D quantiﬁcation of MR severity
by measuring the VC area was performed using
Philips Qlab software as previously described (13).
The 3D mitral valve geometry was assessed at mid-
systole using customized software Omni4D (M.D.
Handschumacher). Mitral annular area, leaﬂet closure
area, tenting volume, tethering length, as well as
interpapillary muscle distance (IPMD), deﬁned as the
distance between the medial and lateral PM tips, were
traced and computed as described previously (11,14).
HEMODYNAMIC ASSESSMENT. Electrocardiogram was
used to monitor arrhythmias and ischemic electro-
cardiographic changes. Acquisition and analysis of
the hemodynamic data were performed using iWorx
LabScribe2 software (iWorx, Inc., Dover, New Hamp-
shire). A 7.0-F conductance catheter (Scisense Inc.,
Ontario, Canada) was inserted transapically to record
LV end-systolic and end-diastolic pressure, maximal
and minimum ﬁrst derivative of pressure measured
over time, and relaxation constant (by Weiss
method). Temporary inferior vena cava occlusion was
performed to evaluate changes in load-independent
variables, including elastance (slope from the end-
systolic pressure volume relationship), stiffness
(slope from the end-diastolic pressure volume rela-
tionship), and slope from the preload–recruitable
stroke work relationship.
HISTOLOGICAL STUDIES. The heart, brain, spleen,
and kidney were excised for histological examinationin a subset of 5 PVA-treated sheep after sacriﬁce
to exclude embolization. Specimens were ﬁxed in
10% formalin, and histopathologic examinations
were performed on 5-mm sections stained with
hematoxylin-eosin.
SAMPLE SIZE AND POWER. We hypothesized that
PVA injection would result in MR reduction from
moderate to severe (VC width $0.5 cm) to trace or
mild (VC width <0.3 cm), which is considered clini-
cally signiﬁcant. To demonstrate such change with
5% a error and 90% power, a minimum of 6 sheep per
group was required.
STATISTICAL ANALYSIS. Measurements were re-
ported as mean  SD for continuous variables.
Differences between groups were analyzed with
unpaired Student t test. Differences in echocardio-
graphic measurements among stages (baseline,
chronic MR, and sacriﬁce) were analyzed by analysis of
variance for repeated measures. Multiple pairwise
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358comparisons were adjusted with Bonferroni correc-
tion. Differences in hemodynamic measurements be-
tween stages were tested by paired t test. A 2-tailed
probability value of 0.05 was considered signiﬁcant.
SPSS software was used for statistical analysis (SPSS
Inc., Chicago, Illinois).
RESULTS
SAMPLE SIZES AND MORTALITY. Twenty-four sheep
underwent ligation of left circumﬂex branches. Eight
animals were excluded (3 sheep died acutely after
MI due to malignant ventricular arrhythmia and 5
developed less than mild MR). A total of 16 sheep that
developed moderate or greater MR 8 weeks after
ligation were further studied. Ten consecutive sheep
(41  4 kg) were treated with an injection of PVA
(3.4  0.6 ml) and 6 sheep (42  4 kg) were treated
with an injection of saline (3.5  0.5 ml). There was no
sudden death after PVA or saline injection. All sheep
were stable and survived up to over 8 weeks after
injection before being sacriﬁced.
MR REDUCTION. Figure 3 shows the changes of MR
severity in the PVA and control groups from the
chronic MR stage to sacriﬁce. At the chronic MR stage,
the MR severity was comparable in both groups.
Acutely after PVA injection, MR decreased from
moderate to trace or mild in all sheep; however, no
beneﬁcial effect was found in the control sheep after
saline injection. Overall, there was persistent MR
reduction 8 weeks after PVA injection (VC width:FIGURE 3 MR Reduction
Comparisons of MR reduction assessed by vena contracta width (A) and
Abbreviations as in Figure 1.0.17  0.08 cm vs. 0.56  0.10 cm, p < 0.001; VC area:
0.06  0.06 cm2 vs. 0.33  0.12 cm2, p < 0.01), whereas
MR degree in the control group progressed to mod-
erate to severe at sacriﬁce. At sacriﬁce, MR severity
in the PVA group was signiﬁcantly lower than that
in the control group (VC width: 0.17  0.08 cm vs.
0.60  0.14 cm, p < 0.001; VC area: 0.06  0.06 cm2 vs.
0.50  0.30 cm2, p < 0.01). Figure 4 shows trace MR
in a PVA-treated sheep versus moderate to severe
MR in a control sheep 8 weeks after injection.
(Figure 4A corresponds to Online Video 1; Figure 4B
corresponds to Online Video 2; Figure 4C corre-
sponds to Online Video 3; Figure 4D corresponds to
Online Video 4).
LV AND LA REMODELING. LV and LA remodeling
over time in both groups are demonstrated in
Figure 5. LV volumes increased signiﬁcantly from
baseline to the chronic MR stage with a signiﬁcant
decrease in EF in both groups (all p < 0.001). LV
volumes, EF, and LA volume were comparable be-
tween the 2 groups at baseline and at the chronic
MR stage. At 8 weeks after PVA injection, compared
with the chronic MR stage, there was no continued
increase in EDV or ESV (EDV: 72.6  15.3 ml vs.
72.7  13.9 ml; ESV: 41.1  10.4 ml vs. 41.0  9.3 ml;
both p > 0.05) and EF remained stable (EF:
43.6  4.6% vs. 43.8  3.4%, p > 0.05). Additionally,
LA volume decreased signiﬁcantly (29.9  6.7 ml vs.
35.7  5.3 ml, p ¼ 0.05) after PVA injection. In
contrast, at 8 weeks after saline injection, LV and LA
volumes continued to increase signiﬁcantly (EDV:vena contracta area (B) between the PVA and control groups.
FIGURE 4 MR Reduction
Chronic PVA application results in persistent MR reduction in a PVA animal (A, B, also see Online Videos 1 and 2). In contrast, no beneﬁcial effect
on MR reduction was found 8 weeks after saline injection in a control sheep (C, D, also see Online Videos 3 and 4). Abbreviations as in Figure 1.
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35991.2  18.0 ml vs. 68.9  19.2 ml; ESV: 55.9  12.4 ml
vs. 40.0  14.5 ml; LA volume: 51.3  4.9 ml vs.
38.1  7.2 ml, all p < 0.05). At sacriﬁce, compared with
the control group, the PVA group had signiﬁcantly
lower LV and LA volumes (EDV: 72.6  15.3 ml
vs. 91.2  18.0 ml, p < 0.05; ESV: 41.1  10.4 ml vs.
55.9  12.4 ml; p < 0.05; LA volume: 29.9  6.7 ml vs.
51.3 4.9ml, p<0.001) and better LV systolic function
(EF: 43.6  4.6% vs. 38.9  3.7%, p ¼ 0.05).
3D MITRAL VALVE GEOMETRY. Table 1 demonstrates
mitral valve geometry over time in both groups
assessed by 3D echocardiography. Mitral annular
area, leaﬂet closure area, tenting volume, tethering
length, and IPMD increased signiﬁcantly from base-
line to the chronic MR stage in both groups. Param-
eters of mitral valve geometry were comparable
between the 2 groups at the chronic MR stage. At 8
weeks after PVA injection, favorable changes werefound in the PVA group, with signiﬁcant decreases in
mitral annular area, leaﬂet closure area, IPMD, and
tenting volume. In contrast, at 8 weeks after saline
injection, IPMD and tenting volume continued to
increase signiﬁcantly with the tendency toward
increase in mitral annular area, leaﬂet closure area,
and tethering length in the control group. At sacri-
ﬁce, the control group, compared with the PVA
group, exhibited signiﬁcantly greater mitral annular
area, leaﬂet closure area, tethering length, IPMD, and
tenting volume.
ELECTROCARDIOGRAPHIC AND HEMODYNAMIC DATA.
During PVA or saline injection, there were no ischemic
electrocardiographic changes or arrhythmias. Eight
sheep in the PVA group and 6 sheep in the control
group had adequate tracing quality for data analysis.
From chronic MR stage to 8 weeks after PVA injection,
hemodynamic data remained stable (Table 2). In
FIGURE 5 LV and LA Remodeling
Comparisons of left ventricular (LV) and left atrial (LA) volumes at all stages between the PVA group and untreated control group. EDV ¼
end-diastolic volume; EF ¼ ejection fraction; ESV ¼ end-systolic volume; other abbreviations as in Figure 1.
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360contrast, at 8 weeks after saline injection, there was a
reduction in elastance and minimum ﬁrst derivative
of pressure measured over time whereas there was an
increase in tau in the control group. However, no
statistically signiﬁcant difference was found between
groups at the chronic MR stage and at sacriﬁce.
PVA MORPHOLOGY AND HISTOLOGY. Gross ana-
tomical examination showed solidiﬁed PVA gel
encapsulated within the posterior-lateral wall sur-
rounded by scar tissue and there was no evidence of
polymer erosion to or through the endo- or epicar-
dial surfaces (Figure 6). The histology examinationshowed encapsulated PVA polymer surrounded by
infarcted myocardium and dense scarring. There was
evidence of expected foreign body giant cell reaction
locally at the PVA-scar interface, typically seen in
reaction to presence of implanted foreign materials
(15). No systemic embolus was found in the brain,
spleen, or kidney.
DISCUSSION
The main results of this study are as follow: 1) injec-
tion of PVA into infarcted myocardium is effective in
treating IMR over 8 weeks of follow-up; 2) this
TABLE 2 Hemodynamic Data
PVA Group Control Group
Chronic MR Sacriﬁce Chronic MR Sacriﬁce
Heart rate, beats/min 93  11 102  15 89  13 90  9
ESP, mm Hg 80  7 76  10 79  10 78  11
EDP, mm Hg 17  6 13  4 16  4 18  6
dP/dtmax, mm Hg/s 1,519  489 1,589  680 1,292  327 1,188  183
dP/dtmin, mm Hg/s –1,138  215 –1,014  257 –1,082  159 –776  209*
Relaxation constant, ms 51  11 57  19 53  5 70  19
Elastance, mm Hg/ml 3.0  1.2 2.8  0.9 3.2  1.4 2.6  1.1*
Stiffness 0.022  0.017 0.014  0.011 0.027  0.01 0.015  0.011
PRSW slope 48  16 57  33 50  9 37  15
Values are mean  SD. *p < 0.05, sacriﬁce vs. chronic MR stage in the control group.
dP/dt ¼ ﬁrst derivative of pressure measured over time; EDP ¼ end-diastolic pressure; ESP ¼ end-systolic
pressure; MR ¼ mitral regurgitation; PRSW ¼ pre-load recruited stroke work; PVA ¼ polyvinyl-alcohol.
TABLE 1 Comparison of Mitral Valve Geometry Between Groups
PVA Group Control Group
Baseline Chronic MR Sacriﬁce Baseline Chronic MR Sacriﬁce
Mitral annular area, cm2 7.87  1.10 9.44  1.41* 8.31  0.82†‡ 8.19  1.21 10.53  0.89* 12.18  2.20
Leaﬂet closure area, cm2 8.72  1.14 11.15  1.52* 9.64  0.84†‡ 9.20  1.15 12.13  0.89* 13.88  2.20
Tethering length, mm 27.3  2.54 32.41  2.30* 30.48  3.09§ 28.04  2.04 32.82  3.11k 34.55  3.29
Interpapillary muscles distance, mm 19.56  3.40 25.57  2.77* 21.80  3.39†§ 17.91  3.16 23.70  3.67 26.70  4.16†
Tenting volume, ml 0.96  0.19 1.78  0.61* 1.42  0.44§¶ 0.91  0.21 1.56  0.08* 2.04  0.30¶
Values are mean  SD. *p < 0.01 vs. baseline of the same group. †p < 0.01 vs. chronic MR stage of the same group. ‡p < 0.01 vs. control group at sacriﬁce. §p < 0.05 vs.
control group at sacriﬁce. kp < 0.05 vs. baseline of the same group. ¶p < 0.05 vs. chronic MR stage of the same group.
MR ¼ mitral regurgitation; PVA ¼ polyvinyl-alcohol.
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361technique stabilizes the mitral-LV complex by cor-
recting leaﬂet tethering and restoring effective
coaptation; and 3) chronic PVA application attenuates
continued LV remodeling in a chronic IMR model.
PERSISTENT MR REDUCTION. The present data
demonstrate that PVA injection acutely reduces IMR,
and more importantly, this favorable effect persists
over 8 weeks without MR recurrence. Other evidence
of chronic efﬁcacy of PVA injection on MR reduction is
supported by LA reverse remodeling. Analysis of
mitral valve geometry by 3D echocardiography con-
ﬁrms that PVA injection attenuates leaﬂet tethering
and improves leaﬂet coaptation geometry over 8
weeks after injection. Our results suggest that chronic
efﬁcacy of PVA injection in persistent MR reduction is
associated with structural stabilization of the mitral-
LV complex by correcting the mitral leaﬂet tethering
and restoring the coaptation. The mechanism of
structural stabilization by PVA may relate to buttress-
ing of the infarcted wall and preventing its bulging.
The result that PVA injection acutely reduces MR in an
acute IMR model also supports an acute and favorable
PM repositioning and reduction in infarct bulging from
PVA injection as a mechanism for MR reduction (10).
EFFECT ON LV REMODELING. Preventing or attenu-
ating LV remodeling has been considered a primary
target for post-MI treatment. The present study
showed that overall EDV, ESV, and EF stabilized
chronically after PVA injection, whereas these beneﬁts
were not observed in the sham-operated control sub-
jects. The favorable effect on stabilization of LV
remodeling and function may relate to reduction of
IMR. Reduction of IMR decreases the volume overload
and stress on the LV andmight subsequently attenuate
the continued LV remodeling process. Beeri et al. (16)
showed that IMR can potentially exacerbate LV
remodeling in a vicious cycle. Early repair of moderate
MR in the setting of apical MI substantially reverses
progressive remodeling process (17). Similarly, Messas
et al. (18) reported chordal cutting diminished MR inthe chronic IMR setting and limited the LV remodeling
seen in control subjects. However, discrepancies still
exist regarding the effect of elimination of IMR on LV
remodeling (19,20). Guy et al. (20) demonstrated in a
sheep model that prevention of LV remodeling and
infarct expansion was achieved by prophylactic ven-
tricular restraint, not by ring annuloplasty, even
though both procedures decreased IMR. Thus, another
potential mechanism for limiting LV remodelingmight
relate to constraint of the infarcted myocardium by
locally applied PVA. Restraint of infarct expansion
using an external patch preserved both LV geometry
and cardiac function (9). LV restraint could also be
achieved less invasively by direct injection of bio-
materials, such as ﬁbrin, collagen, or alginate
hydrogel into the infarcted zone to reshape and
buttress the bulging LV (21,22). Studies have shown
that injection of biomaterials replaces damaged
extracellular matrix and thickens the infarcted wall.
By thickening the damaged area, wall stress is
decreased, and subsequently reduces the paradoxical
motion caused by infarct thinning and limits the
adverse LV remodeling and dysfunction. Wall et al.
(23) conﬁrmed this beneﬁt in a computer modeling
FIGURE 6 PVA Morphology
Gross appearance of polyvinyl-alcohol (PVA) polymer (white oval) injected into chronic
infarction for over 8 weeks.
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362study, showing that implanting noncontractile ma-
terials into damaged myocardium can decrease end-
systolic ﬁber stress. Moreover, the injection resulted
in the improvement of EF and stroke volume–EDV
relationship. An advantage of PVA hydrogel is that it
forms a stable, nondegradable, inert gel, making it
ideal for chronic use. Ifkovits et al. (24) were the ﬁrst
to explore the effects of the mechanical properties of
injectable materials on post-MI LV remodeling. They
found injection of higher mechanical modulus
hydrogel (43 kPa) in an ovine model limited the
infarct expansion, prevented LV remodeling, and
improved cardiac function when compared with
lower modulus hydrogel (8 kPa) in an infarct control
group (24). This is evidence that hydrogel injection
attenuates LV remodeling, which depends on
hydrogel mechanics, and the higher modulus hydro-
gel is better able to stabilize the myocardium. The
PVA polymer used in the present study has a simi-
larly high mechanical modulus, which solidiﬁes at
body temperature after injection and forms a hard
substance localized within the infarct zone acting as
an internal stiffener or tissue-bulking agent.
In our study, although the overall EDV and ESV did
not change signiﬁcantly, 8 weeks after PVA injection,
mild continued LV remodeling was noted in 3 animals.
This is similar to the clinically observed variability in
extent of remodeling or wall bulging among patients
with a comparable inferoposterior MI territory.
Considering that PVA is locally applied, global LVremodeling would still be expected to progress in the
border zone or remote area. In contrast, signiﬁcant
continued LV remodeling was observed in all the
control animals, which might be attributable to both
persistent MR and infarct expansion.
CLINICAL IMPLICATIONS. Injection of PVA hydrogel
into infarcted myocardium is a novel comprehensive
approach to treating IMR by speciﬁcally targeting its
causative mechanism in the beating heart. Compared
with surgical ring annuloplasty, PVA injection offers
an alternative therapy for treating IMR that directly
addresses the LV distortion and tethering mechanism.
Recently, percutaneous mitral valve repair MitraClip
(Abbott, Abbott Park, Illinois) has been approved for
degenerative mitral valve disease and is currently
undergoing a clinical trial to assess efﬁcacy in func-
tionalMR (25). Importantly, PVA injectionmight add to
current therapies for IMR and may prove useful as a
stand-alone therapy for IMR or in conjunction with
ring annuloplasty or MitraClip therapy.
Additionally, a fundamental limitation of ring
annuloplasty is a signiﬁcant recurrence rate of IMR
that results from persistent leaﬂet tethering in the
setting of continued LV remodeling. Injection of PVA
hydrogel into the infarcted myocardium over the PM
has the potential to both reduce MR by decreasing
leaﬂet tethering but also to stabilize LV geometry and
attenuate adverse LV remodeling by acting as an
internal constraint. This present study demonstrates
that localized PVA injection has prolonged efﬁcacy
with chronic follow-up after injection into the heart
with a chronically remodeled MI. These results pro-
vide important insights and suggest the potential
clinical application of a new therapeutic approach in
patients with IMR. At this stage, injection of PVA is
performed via thoracotomy, but is less invasive than
other surgical strategies that target the LV distortion
or leaﬂet tethering, such as infarct plication or
surgical relocation of the PM. Development of a
catheter-based approach would hold promise for
future minimally invasive percutaneous delivery and
injection. Devices to stabilize the needle system
platform against the myocardium and syringes with
set PVA volumes to standardize delivery volumes can
be adopted for percutaneous injection.
STUDY LIMITATIONS. First, several factors including
the size of infarction, sites of injection, and amount of
polymer injected potentially contribute to the efﬁ-
cacy of this treatment. These variables may limit the
results in clinical investigation. Second, due to the
data variations, this study might be underpowered to
demonstrate the hemodynamic beneﬁt of the PVA
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363group over the control group at sacriﬁce. Third, the
model of the present experiment is an asymmetric
tethering model resulting from posterolateral MI, the
most clinically relevant scenario. The beneﬁts of PVA
injection can also be studied in the future for more
extensive myocardial infarction involving both PM or
the anterior wall, with potentially prominent annular
dilation. Fourth, the beneﬁcial effects were observed
over 8 weeks after the injection of PVA. Future
investigation can explore longer time periods to
evaluate the durability of this procedure, as late
adverse remodeling after ring annuloplasty with
recurrent MR is frequently seen years after the pro-
cedure, but the timing used enabled demonstration of
maintained reduction of MR and tethering.CONCLUSIONS
Chronic polymer injection in a chronic IMR model
results in persistent reduction of MR and attenuation
of continued LV remodeling over 8 weeks of follow-
up. This suggests an alternative approach to the
treatment of IMR with maintained efﬁcacy over time.
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